2. Search Result
Search Result
Results for "

postsynaptic

" in MedChemExpress (MCE) Product Catalog:

50

Inhibitors & Agonists

1

Screening Libraries

10

Peptides

6

Natural
Products

1

Recombinant Proteins

2

Isotope-Labeled Compounds

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117575A
    WAY-100135 dihydrochloride

    		5-HT Receptor Neurological Disease
    WAY-100135 dihydrochloride is a selective antagonist at presynaptic and postsynaptic 5-HT1A receptor, with an IC50 of 34 nM at the rat hippocampal 5-HT1A receptor. WAY-100135 dihydrochloride has potential antipsychotic properties .
    WAY-100135 dihydrochloride
  • HY-145454
    (R)-Preclamol

    (+)-3-PPP

    		 Dopamine Receptor Neurological Disease
    (R)-Preclamol is a dopamine (DA) agonist with autoreceptor as well as postsynaptic receptor stimulatory properties. (R)-Preclamol inhibits the locomotor activity of mice and rats in low doses .
    (R)-Preclamol
  • HY-B0098S
    Doxazosin-d8

    UK 33274 d8

    		 Isotope-Labeled Compounds Adrenergic Receptor Cardiovascular Disease Endocrinology
    Doxazosin-d8 is a deuterium labeled Doxazosin (UK 33274). Doxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic α1 adrenergic receptors[1].
    Doxazosin-d8
  • HY-145454A
    Preclamol

    (-)-3-PPP

    		 Dopamine Receptor Neurological Disease
    Preclamol is a dopamine (DA) agonist with autoreceptor as well as postsynaptic receptor stimulatory properties. Preclamol inhibits the locomotor activity of mice and rats in low doses .
    Preclamol
  • HY-B1789
    Telenzepine

    		mAChR Neurological Disease
    Telenzepine is an antimuscarinic agent with Kis of 0.94 nM (M1 mAChR) and 17.8 nM (M2 mAChR) binding to muscarinic receptors. Telenzepine effectively blocks synaptic transmission promoted by muscarinic or M1 receptor agonists. Thus, Telenzepine can reduce the amplitude of extracellular slow excitatory postsynaptic potentials (EC50=38 nM) and slow inhibitory postsynaptic potentials (EC50=253 nM) .
    Telenzepine
  • HY-119615
    Mezilamine

    		Adrenergic Receptor Neurological Disease Endocrinology
    Mezilamine is a potent antidopaminergic agent. Mezilamine induces a concentration dependent increase in the electrically stimulated overflow of 3H-noradrenaline from rat cortical slices, without affecting the basal overflow. Mezilamine acts as a presynaptic α-adrenoceptor antagonist and a postsynaptic α-adrenoceptor agonist .
    Mezilamine
  • HY-19733
    Lumateperone tosylate

    ITI-007 tosylate

    		 5-HT Receptor Dopamine Receptor Neurological Disease
    Lumateperone (ITI-007) tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator. Lumateperone tosylate has anticancer activity and can also be used in studies of psychiatric disorders such as schizophrenia .
    Lumateperone tosylate
  • HY-100255
    Tiodazosin

    BL-5111

    		 Adrenergic Receptor Neurological Disease Endocrinology
    Tiodazosin is a potent competitive postsynaptic alpha adrenergic receptor antagonist.
    Tiodazosin
  • HY-110175
    CX614

    		iGluR Neurological Disease
    CX614 is a positive variant modulator of AMPA receptors that enhances excitatory postsynaptic potentials (amplitude and duration) by blocking and slowing the inactivation of responses to glutamate and automatically evokes excitatory postsynaptic currents in neuronal cultures. CX614 can be used in the study of psychiatric disorders such as depression .
    CX614
  • HY-106888
    CS-722 Free base

    		Endogenous Metabolite Neurological Disease
    CS-722 Free base is a synthesized centrally acting muscle relaxant, and has a muscle relaxant activity and depressant effectson the spinal reflex . CS-722 Free base inhibits spontaneous inhibitory postsynaptic currents and excitatory postsynaptic currents in hippocampal cultures probably by an inhibition of both sodium and calcium currents .
    CS-722 Free base
  • HY-B0098A
    Doxazosin mesylate
    1 Publications Verification

    UK 33274 mesylate

    		 Adrenergic Receptor Autophagy Mitophagy Cardiovascular Disease Endocrinology Cancer
    Doxazosin mesylate (UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors.
    Doxazosin mesylate
  • HY-B0098
    Doxazosin

    UK 33274

    		 Adrenergic Receptor Cardiovascular Disease Endocrinology
    Doxazosin (UK 33274) is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors.
    Doxazosin
  • HY-101322A
    MM 77 dihydrochloride

    MM 77 dihydrochloride is a potent postsynaptic antagonist of the 5-HT1A receptor. MM 77 dihydrochloride exhibits anxiolytic-like activity .
    MM 77 dihydrochloride
  • HY-145475
    Nervonoyl ethanolamide

    NEA

    		 Others Neurological Disease Inflammation/Immunology
    Nervonoyl ethanolamide (NEA) is an endogenous cannabinoid that can act as a presynaptic and postsynaptic neuromodulator. Nervonoyl ethanolamide can also be used in the research of inflammation .
    Nervonoyl ethanolamide
  • HY-N2550
    (+)-Coclaurine

    (+)-(R)-Coclaurine; (R)-Coclaurine; d-Coclaurine

    		 Others Neurological Disease
    (+)-Coclaurine ((+)-(R)-Coclaurine), benzyltetrahydroisoquinoline alkaloid isolated from a variety of plant sources. (+)-Coclaurine has anti-aging activity .
    (+)-Coclaurine
  • HY-N2550A
    (+)-Coclaurine hydrochloride

    (+)-(R)-Coclaurine hydrochloride; (R)-Coclaurine hydrochloride; d-Coclaurine hydrochloride

    		 Others Neurological Disease
    (+)-Coclaurine ((+)-(R)-Coclaurine) hydrochloride, benzyltetrahydroisoquinoline alkaloid isolated from a variety of plant sources. (+)-Coclaurine hydrochloride has anti-aging activity .
    (+)-Coclaurine hydrochloride
  • HY-108698A
    (R)-Preclamol hydrochloride

    (+)-3-PPP hydrochloride

    		 Dopamine Receptor Neurological Disease
    (R)-Preclamol hydrochloride ((+)-3-PPP hydrochloride) is the R-enantiomer of Preclamol hydrochloride. (R)-Preclamol hydrochloride is a DA agonist with autoreceptor as well as postsynaptic receptor stimulatory properties .
    (R)-Preclamol hydrochloride
  • HY-N0127
    Yohimbine Hydrochloride
    Maximum Cited Publications
    10 Publications Verification

    		 Adrenergic Receptor Endocrinology
    Yohimbine Hydrochloride is an alpha 2-adrenoreceptor antagonist, blocking the pre- and postsynaptic alpha-2 adrenoreceptors and causing an increased release of noradrenaline and dopamine.
    Yohimbine Hydrochloride
  • HY-N2833
    Akuammigine

    		Adrenergic Receptor Neurological Disease
    Akuammigine is an alkaloid that can be found in hook-bearing branch of Uncariarhynchophylla. Akuammigine is a is a very weak antagonist at pre- and postsynaptic α-adrenoceptor of the rat vas deferens .
    Akuammigine
  • HY-A0171A
    Benzoctamine hydrochloride

    Ba-30803

    		 5-HT Receptor Neurological Disease
    Benzoctamine hydrochloride (Ba-30803) is a psychoactive agent with anti-anxiety effect. Benzoctamine hydrochloride blocks the central postsynaptic serotonin receptors and decreases 5-HT turnover in the brain .
    Benzoctamine hydrochloride
  • HY-100813
    Saclofen
    3 Publications Verification
    Saclofen is a competitive antagonist of the GABAB receptor with an IC50 of 7.8 μM. Saclofen can be used to determine the functional roles for the GABAB receptor as a mediator of slow inhibitory postsynaptic potentials in the brain .
    Saclofen
  • HY-100372
    E4CPG

    (RS)-ECPG

    		 mGluR Neurological Disease
    E4CPG ((RS)-ECPG) is a Group I/Group II metabotropic glutamate receptor (mGluR) antagonist. E4CPG can inhibit the paired-pulse ratio of monosynaptic inhibitory postsynaptic currents (IPSC) potentiation .
    E4CPG
  • HY-B1396
    Nefazodone hydrochloride
    1 Publications Verification

    BMY-13754; MJ-13754-1

    		 5-HT Receptor Adrenergic Receptor Neurological Disease Endocrinology
    Nefazodone hydrochloride (BMY-13754) is a potent and selective 5HT2A (Ki=5.8 nM) antagonist with moderate inhibition of 5-HT and noradrenaline uptake (IC50 of 290 and 300 nM, respectively). Nefazodone hydrochloride is a phenylpiperazine antidepressant with less alpha-adrenergic blocking activity .
    Nefazodone hydrochloride
  • HY-P5859
    α-Pompilidotoxin

    α-PMTX

    		 Biochemical Assay Reagents Neurological Disease
    α-Pompilidotoxin (α-PMTX) is a neurotoxin that can be obtained from the venom of Anoplius safnariensis. α-Pompilidotoxin reversibly and dose-dependently enhances excitatory postsynaptic currents (EPSCs). α-Pompilidotoxin is a useful tool in the field of neuroscience research .
    α-Pompilidotoxin
  • HY-12237
    SKF 38393 hydrobromide

    (±)-SKF-38393 hydrobromide

    		 Dopamine Receptor Neurological Disease
    SKF 38393 ((±)-SKF-38393) hydrobromide is a selective agonist of the dopamine D1 receptor (D1DR) with an IC50 of 110 nM .
    SKF 38393 hydrobromide
  • HY-P1297
    CRF(6-33)(human)

    		CRFR Neurological Disease
    CRF(6-33)(human) is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) has anti-obesity effect .
    CRF(6-33)(human)
  • HY-107601
    UBP316

    ACET

    		 iGluR Neurological Disease
    UBP316 (ACET) is a highly potent and selective kainate receptor GluK1 (GluR5) antagonist, with a Kb value of 1.4 nM. UBP316 is effective at blocking the depression of both field excitatory postsynaptic potentials (fEPSPs) and monosynaptically-evoked GABAergic transmission induced by ATPA, a GluK1 selective agonist .
    UBP316
  • HY-P4397
    (d(CH2)51,Tyr(Me)2,Thr4,Orn8,des-Gly-NH29)-Vasotocin

    		Oxytocin Receptor Endocrinology
    (d(CH2)51,Tyr(Me)2,Thr4,Orn8,des-Gly-NH29)-Vasotocin, an oxytocin receptor antagonist, abolishes oxytocin-enhanced inhibitory postsynaptic currents in CA1 pyramidal neurons .
    (d(CH2)51,Tyr(Me)2,Thr4,Orn8,des-Gly-NH29)-Vasotocin
  • HY-116431
    I-BOP

    		Prostaglandin Receptor Cardiovascular Disease Neurological Disease
    I-BOP is an agonist for thromboxane A2 receptor (TP) with a KD of 0.61 nM. I-BOP promotes proliferation through activation of PI3K pathway in vascular smooth muscle . I-BOP dose-dependently biphasicly affects the excitatory postsynaptic potential (e.p.s.p.) in hippocampal neurons .
    I-BOP
  • HY-P1297A
    CRF(6-33)(human) TFA

    		CRFR Neurological Disease
    CRF(6-33)(human) TFA is a CRF binding protein (CRF-BP) ligand inhibitor. CRF(6-33)(human) TFA competitively binds the CRF-BP but not the post-synaptic CRF receptors. CRF(6-33)(human) TFA has anti-obesity effect .
    CRF(6-33)(human) TFA
  • HY-P2471
    Neurogranin (48-76), mouse

    		Calmodulin Neurological Disease
    Neurogranin (48-76), mouse is a peptide corresponding to residues 48-76 of Neurogranin. Neurogranin, a calmodulin-binding protein, is exclusively expressed in the post-synapse, and mediates NMDAR driven synaptic plasticity by regulating the calcium-calmodulin (Ca 2+-CaM) pathway .
    Neurogranin (48-76), mouse
  • HY-P0099
    Pentapeptide-3

    Pentapeptide-3 is a pentapeptide fragment of neurotoxin waglerin-1, it can be extracted from the venom of Temple Viper. Pentapeptide-3 is a competitive antagonist of nicotinic acetylcholine receptors (nAChRs), it can blocks nerves at the post-synaptic membrane. Pentapeptide-3 has anti-aging effects and it can be used together with other cosmetic peptides .
    Pentapeptide-3
  • HY-17637
    Lumateperone

    ITI-007
    Lumateperone (ITI-007) is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator. Lumateperone has anticancer activity and can also be used in studies of psychiatric disorders such as schizophrenia .
    Lumateperone
  • HY-116076
    S-15535

    		5-HT Receptor Neurological Disease
    S-15535 is a highly selective 5-HT1A receptor ligand. S-15535 is an antagonist of postsynaptic 5-HT1A receptors and an agonist of presynaptic 5-HT1A receptors. S-15535 can be used in research on psychiatric disorders, such as anti-anxiety .
    S-15535
  • HY-P1195
    PDZ1 Domain inhibitor peptide

    		iGluR Neurological Disease
    PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
    PDZ1 Domain inhibitor peptide
  • HY-P1195A
    PDZ1 Domain inhibitor peptide TFA

    		iGluR Neurological Disease
    PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
    PDZ1 Domain inhibitor peptide TFA
  • HY-119209
    Nefazodone
    1 Publications Verification

    		 5-HT Receptor Cytochrome P450 Neurological Disease Inflammation/Immunology
    Nefazodone is an orally active phenylpiperazine antidepressant. Nefazodone can potently and selectively block postsynaptic 5-HT2A receptors, and moderately inhibit 5-HT and noradrenaline reuptake. Nefazodone can also relieve the adverse effects of stress on the the immune system of mice. Nefazodone has a high affinity for CYP3A4 isoenzyme, which indicates that it has certain risk of agent-agent interaction .
    Nefazodone
  • HY-13527
    LY310762
    1 Publications Verification

    		 5-HT Receptor Cardiovascular Disease Neurological Disease
    LY310762 is a selective 5-HT1D receptor antagonist (Ki=249 nM) with a weak affinity for 5-HT1B receptor. LY310762 effectively abolishes the renal vasodilatory effects of 5-HTSumatriptan (HY-B0121B)-induced decrease in excitatory postsynaptic potential (EPSC) amplitude .
    LY310762
  • HY-111283
    AJ-76

    (+)-AJ 76; (1S,2R)-AJ 76

    		 Dopamine Receptor Neurological Disease
    AJ-76 ((+)-AJ 76; (1S,2R)-AJ 76) is a dopamine autoreceptor antagonist. AJ-76 can increase the synthesis and turnover of dopamine in the rat brain, while having little effect on the synthesis and turnover of serotonin (5-HT) and norepinephrine. AJ-76 can also antagonize the sedative effects of low-dose apomorphine and has a weak antagonistic effect on postsynaptic dopamine receptor .
    AJ-76
  • HY-A0081
    Fluphenazine dihydrochloride

    		Dopamine Receptor SARS-CoV Sodium Channel Neurological Disease Cancer
    Fluphenazine dihydrochloride is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine dihydrochloride blocks neuronal voltage-gated sodium channels. Fluphenazine dihydrochloride acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine dihydrochloride can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine dihydrochloride can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 .
    Fluphenazine dihydrochloride
  • HY-119980
    Fluphenazine

    		Sodium Channel Dopamine Receptor SARS-CoV Infection Neurological Disease
    Fluphenazine is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine blocks neuronal voltage-gated sodium channels. Fluphenazine acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 .
    Fluphenazine
  • HY-119980B
    Fluphenazine hydrochloride

    		Dopamine Receptor Sodium Channel SARS-CoV Neurological Disease
    Fluphenazine hydrochloride is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine hydrochloride blocks neuronal voltage-gated sodium channels. Fluphenazine hydrochloride acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine hydrochloride can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine hydrochloride can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 .
    Fluphenazine hydrochloride
  • HY-N0215
    L-Phenylalanine

    Phenylalanine

    		 Calcium Channel iGluR Endogenous Metabolite Metabolic Disease
    L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca + channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals .
    L-Phenylalanine
  • HY-100403
    Ro 67-7476
    5+ Cited Publications

    		 mGluR Cancer
    Ro 67-7476 is a potent positive allosteric modulator of mGluR1 and potentiates glutamate-induced calcium release in HEK293 cells expressing rat mGluR1a with an EC50 of 60.1 nM . Ro 67-7476 is a potent P-ERK1/2 agonist and activates ERK1/2 phosphorylation in the absence of exogenously added glutamate (EC50=163.3 nM) .
    Ro 67-7476
  • HY-119980A
    Fluphenazine dimaleate

    		Dopamine Receptor Sodium Channel SARS-CoV Infection Neurological Disease
    Fluphenazine dimaleate is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine dimaleate blocks neuronal voltage-gated sodium channels. Fluphenazine dimaleate acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine dimaleate can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine dimaleate can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 .
    Fluphenazine dimaleate
  • HY-119980S
    Fluphenazine-d8

    		Isotope-Labeled Compounds Sodium Channel Dopamine Receptor SARS-CoV Others
    Fluphenazine-d8 is the deuterium labeled Fluphenazine. Fluphenazine is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine blocks neuronal voltage-gated sodium channels. Fluphenazine acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 .
    Fluphenazine-d8
  • HY-156104
    CaMKIIα-PHOTAC

    		PROTACs CaMK Neurological Disease
    CaMKIIα-PHOTAC is a photochemically targeted chimera (PHOTAC) targeting Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα). Molecules such as PHOTAC can catalyze the ubiquitination and degradation of target proteins through the endogenous proteasome under specific wavelengths of light. CaMKIIα-PHOTAC reduces synaptic function under light conditions, and it attenuates the intensity of evoked field excitatory postsynaptic potentials in the mouse hippocampus in response to physiological stimuli. CaMKIIα-PHOTAC plays a critical role in maintaining long-term potentiation and memory capacity in subcellular dendritic domains .
    CaMKIIα-PHOTAC
  • HY-A0081R
    Fluphenazine dihydrochloride (Standard)

    		Dopamine Receptor SARS-CoV Sodium Channel Neurological Disease Cancer
    Fluphenazine (dihydrochloride) (Standard) is the analytical standard of Fluphenazine (dihydrochloride). This product is intended for research and analytical applications. Fluphenazine dihydrochloride is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine dihydrochloride blocks neuronal voltage-gated sodium channels. Fluphenazine dihydrochloride acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine dihydrochloride can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine dihydrochloride can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2 .
    Fluphenazine dihydrochloride (Standard)
  • HY-P0117A
    Tat-NR2B9c TFA
    5+ Cited Publications

    Tat-NR2Bct TFA; NA-1 TFA

    		 iGluR NO Synthase Neurological Disease
    Tat-NR2B9c TFA (Tat-NR2Bct TFA) is a postsynaptic density-95 (PSD-95) inhibitor, with EC50 values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c TFA disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC50 values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c TFA also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy .
    Tat-NR2B9c TFA
  • HY-P0117
    Tat-NR2B9c
    5+ Cited Publications

    Tat-NR2Bct; NA-1

    		 iGluR NO Synthase Neurological Disease
    Tat-NR2B9c (Tat-NR2Bct; NA-1) is a postsynaptic density-95 (PSD-95) inhibitor, with EC50 values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC50 values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy .
    Tat-NR2B9c

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: